Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/102944
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia |
Author: | Weickert, T. Weinberg, D. Lenroot, R. Catts, S. Wells, R. Vercammen, A. O'Donnell, M. Galletly, C. Liu, D. Balzan, R. Short, B. Pellen, D. Curtis, J. Carr, V. Kulkarni, J. Schofield, P. Weickert, C. |
Citation: | Molecular Psychiatry, 2015; 20(6):685-694 |
Publisher: | Nature Publishing Group |
Issue Date: | 2015 |
ISSN: | 1359-4184 1476-5578 |
Statement of Responsibility: | TW Weickert, D Weinberg, R Lenroot, SV Catts, R Wells, A Vercammen, M O, Donnell, C Galletly, D Liu, R Balzan, B Short, D Pellen, J Curtis, VJ Carr, J Kulkarni, PR Schofield and CS Weickert |
Abstract: | There is increasing clinical and molecular evidence for the role of hormones and specifically estrogen and its receptor in schizophrenia. A selective estrogen receptor modulator, raloxifene, stimulates estrogen-like activity in brain and can improve cognition in older adults. The present study tested the extent to which adjunctive raloxifene treatment improved cognition and reduced symptoms in young to middle-age men and women with schizophrenia. Ninety-eight patients with a diagnosis of schizophrenia or schizoaffective disorder were recruited into a dual-site, thirteen-week, randomized, double-blind, placebocontrolled, crossover trial of adjunctive raloxifene treatment in addition to their usual antipsychotic medications. Symptom severity and cognition in the domains of working memory, attention/processing speed, language and verbal memory were assessed at baseline, 6 and 13 weeks. Analyses of the initial 6-week phase of the study using a parallel groups design (with 39 patients receiving placebo and 40 receiving raloxifene) revealed that participants receiving adjunctive raloxifene treatment showed significant improvement relative to placebo in memory and attention/processing speed. There was no reduction in symptom severity with treatment compared with placebo. There were significant carryover effects, suggesting some cognitive benefits are sustained even after raloxifene withdrawal. Analysis of the 13-week crossover data revealed significant improvement with raloxifene only in attention/processing speed. This is the first study to show that daily, oral adjunctive raloxifene treatment at 120 mg per day has beneficial effects on attention/processing speed and memory for both men and women with schizophrenia. Thus, raloxifene may be useful as an adjunctive treatment for cognitive deficits associated with schizophrenia. |
Keywords: | Humans Memory Disorders Estrogen Antagonists Treatment Outcome Statistics, Nonparametric Longitudinal Studies Cross-Over Studies Double-Blind Method Patient Compliance Attention Deficit Disorder with Hyperactivity Schizophrenia Psychiatric Status Rating Scales Neuropsychological Tests Sex Characteristics Adolescent Adult Middle Aged Australia Female Male Young Adult Raloxifene Hydrochloride |
Rights: | © 2015 Macmillan Publishers Limited All rights reserved. This work is licensed under a Creative Commons Attribution- NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if thematerial is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http:// creativecommons.org/licenses/by-nc-nd/4.0/ |
DOI: | 10.1038/mp.2015.11 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/568807 |
Published version: | http://dx.doi.org/10.1038/mp.2015.11 |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_102944.pdf | Published version | 645.02 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.